Contemporary use of balloon aortic valvuloplasty in the era of transcatheter aortic valve implantation

• Published in: Texas Heart Institute journal Vol. 41; no. 5; pp. 469 - 476
• Main Authors: Hui, Dawn S, Shavelle, David M, Cunningham, Mark J, Matthews, Ray V, Starnes, Vaughn A
• Format: Journal Article
• Language: English
• Published: United States Texas Heart® Institute, Houston 01.10.2014
• Subjects: Adult; Aged; Aged, 80 and over; Aortic Valve Stenosis - mortality; Aortic Valve Stenosis - surgery; Balloon Valvuloplasty; Clinical Investigation; Female; Hospital Mortality; Humans; Male; Middle Aged; Patient Selection; Retrospective Studies; Tertiary Care Centers; Transcatheter Aortic Valve Replacement; Treatment Outcome; balloon valvuloplasty/adverse effects/methods/mortality; patient selection; heart valve prosthesis implantation/methods; Aortic valve stenosis/therapy; risk assessment/methods; treatment outcome; disease management
• ISSN: 0730-2347; 1526-6702
• DOI: 10.14503/thij-13-3757

The development of transcatheter aortic valve implantation (TAVI) has increased the use of balloon aortic valvuloplasty (BAV) in treating aortic stenosis. We evaluated our use of BAV in an academic tertiary referral center with a developing TAVI program. We reviewed 69 consecutive stand-alone BAV procedures that were performed in 62 patients (mean age, 77 ± 10 yr; 62% men; baseline mean New York Heart Association functional class, 3 ± 1) from January 2009 through December 2012. Enrollment for the CoreValve(®) clinical trial began in January 2011. We divided the study cohort into 2 distinct periods, defined as pre-TAVI (2009-2010) and TAVI (2011-2012). We reviewed clinical, hemodynamic, and follow-up data, calculating each BAV procedure as a separate case. Stand-alone BAV use increased 145% from the pre-TAVI period to the TAVI period. The mean aortic gradient reduction was 13 ± 10 mmHg. Patients were successfully bridged as intended to cardiac or noncardiac surgery in 100% of instances and to TAVI in 60%. Five patients stabilized with BAV subsequently underwent surgical aortic valve replacement with no operative deaths. The overall in-hospital mortality rate (17.4%) was highest in emergent patients (61%). The implementation of a TAVI program was associated with a significant change in BAV volumes and indications. Balloon aortic valvuloplasty can successfully bridge patients to surgery or TAVI, although least successfully in patients nearer death. As TAVI expands to more centers and higher-risk patient groups, BAV might become integral to collaborative treatment decisions by surgeons and interventional cardiologists.